摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(3R)-3-羟基-1-哌啶基]乙酮 | 732245-90-8

中文名称
1-[(3R)-3-羟基-1-哌啶基]乙酮
中文别名
——
英文名称
1-[(3R)-3-hydroxypiperidin-1-yl]ethan-1-one
英文别名
N-acetyl-(R)-3-hydroxypiperidine;1-((R)3-hydroxypiperidin-1-yl)ethanone;1-((R)-3-Hydroxy-piperidin-1-yl)-ethanone;1-[(3R)-3-hydroxypiperidin-1-yl]ethanone
1-[(3R)-3-羟基-1-哌啶基]乙酮化学式
CAS
732245-90-8
化学式
C7H13NO2
mdl
——
分子量
143.186
InChiKey
HTFMTRPNNXNQRN-SSDOTTSWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    40.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:ee31591c1caa2918ce6351641f4d7715
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin
    摘要:
    We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitroaromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.
    DOI:
    10.1021/ml100138q
  • 作为产物:
    描述:
    1-乙酰基哌啶-3-酮 在 Daucus carota 、 作用下, 以 乙醇 为溶剂, 反应 48.0h, 生成 1-[(3R)-3-羟基-1-哌啶基]乙酮3-羟基-1-乙酰基-哌啶
    参考文献:
    名称:
    Daucus carota Mediated-Reduction of Cyclic 3-Oxo-amines
    摘要:
    Carrots (Daucus carota) were used to reduce cyclic amino-ketones in high yields and enantiomeric excesses. This cheap, eco-compatible, and efficient reducing reagent allows the easy access to precursors of biologically active products.
    DOI:
    10.1021/ol8029214
点击查看最新优质反应信息

文献信息

  • Syntheses of ureas
    申请人:Morgan Paul Bradley
    公开号:US20060025470A1
    公开(公告)日:2006-02-02
    The present invention provides intermediates, synthetic methods and novel urea compositions of matter.
    本发明提供了中间体、合成方法和新型脲类物质组合。
  • Compounds, compositions and methods
    申请人:Morgan Paul Bradley
    公开号:US20050159416A1
    公开(公告)日:2005-07-21
    Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    某些取代脲衍生物可以选择性地调节心脏肌肉纤维,例如通过增强心脏肌球蛋白,因此在治疗收缩性心力衰竭,包括充血性心力衰竭方面具有用处。
  • Compounds, Compositions and Methods
    申请人:Morgan Bradley Paul
    公开号:US20090176307A1
    公开(公告)日:2009-07-09
    Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    某些取代脲衍生物可以选择性地调节心脏肌肉节段,例如通过增强心肌肌球蛋白,因此可用于治疗收缩性心力衰竭,包括充血性心力衰竭。
  • [EN] ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ARYLES COMME BLOQUEURS DES CANAUX POTASSIQUES SHAKER KV1.3
    申请人:DE SHAW RES LLC
    公开号:WO2022212296A1
    公开(公告)日:2022-10-06
    A compound of Formula (I), (I'), (II), (II'), (III), or (IV) or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
    本文介绍了化合物I、I'、II、II'、III或IV的配方,或其药学上可接受的盐,其中取代基的定义如本文所述。还描述了包含上述化合物的药物组合物和使用该组合物的方法。
  • Compounds, compositions and methods of treatment for heart failure
    申请人:Cytokinetics, Inc.
    公开号:EP2397462A2
    公开(公告)日:2011-12-21
    Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    某些取代的脲衍生物可选择性地调节心肌肌节,例如通过增强心肌肌球蛋白的作用,可用于治疗收缩性心力衰竭,包括充血性心力衰竭。
查看更多